Biomarkers of Alzheimer's disease and mild cognitive impairment: Are we there yet?

Experimental Neurology

Volumn 183, Issue 1, 2003, Pages 7-10

  Turner, R Scott ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; 8 HYDROXYDEOXYGUANOSINE; ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CHOLESTEROL DERIVATIVE; FLUORODEOXYGLUCOSE F 18; GLIAL FIBRILLARY ACIDIC PROTEIN; IRON BINDING PROTEIN; ISOPROSTANE DERIVATIVE; NEURONAL THREAD PROTEIN; PHOSPHOTHREONINE 181 TAU PROTEIN; PRESENILIN 1; PRESENILIN 2; PROTEIN P97; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN ATROPHY; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MULTIINFARCT DEMENTIA; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TASK PERFORMANCE;

EID: 0042691313     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4886(03)00203-6     Document Type: Note

References (14)

1. Braak H., Braak E. Neuropathologic staging of Alzheimer related changes. Acta Neuropathol. 82:1991;239-259.
2. Diagnostic and Statistical Manual of Mental Disorders. 4th ed :1994;American Psychiatric Association, Washington, DC.
3. Doody R.S., Stevens J.C., Beck C., et al. Practice parameter management of dementia (an evidence-based review) . Neurology. 56:2001;1154-1166.
4. Galasko D. Biological markers and the treatment of Alzheimer's disease. J. Mol. Neurosci. 17:2001;119-125.
5. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease progress and problems on the road to therapeutics . Science. 297:2002;353-356.
6. Hedera P., Turner R.S. Inherited dementias. Lynch D.R., Farmer J.M. Neurologic Clinics of North America. 20:2002;779-808 Saunders, Philadelphia.
7. Knopman D.S., DeKosky S.T., Cummings J.L., et al. Practice parameter diagnosis of dementia (an evidence-based review) . Neurology. 56:2001;1143-1153.
8. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease . Neurology. 34:1984;939-944.
9. Mirra S.S., Heyman A., McKeel D., et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 41:1991;479-486.
10. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol. Aging. 18:1997;S1-S2.
11. Olsson A., Höglund K., Sjögren M., Andreasen N., Minthon L., Lannfelt L., Buerger K., Möller H.-J., Hampel H., Davidsson P., Blennow K. Measurement of α- and β-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp. Neurol. 183:2003;74-80.
12. Petersen R.C., Stevens J.C., Ganguli M., et al. Practice parameter mild cognitive impairment (an evidence-based review) . Neurology. 56:2001;1133-1142.
13. Teunissen C.E., de Vente J., Steinbusch H.W.M., De Bruijn C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol. Aging. 23:2002;485-508.
14. Consensus report of the working group on "Molecular and Biochemical Markers of Alzheimer's Disease" Neurobiol. Aging. 19:1998;109-116.